NCT06459869 - NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 7, 2025

Primary Completion Date

February 28, 2026

Study Completion Date

January 30, 2029

Conditions

Locally Advanced Rectal Cancer (LARC)

Interventions

DRUG

NG-350A IV administration

a tumour-selective anti-CD40-expressing adenoviral vector

DRUG

Capecitabine oral administration

chemotherapy

RADIATION

Radiotherapy

long-course intensity-modulated radiotherapy

Trial Locations (4)

RECRUITING

Ohio State University Comprehensive Cancer Center, Columbus

RECRUITING

The University of Texas MD Anderson Cancer Center, Houston

RECRUITING

University College London NHS FT, London

RECRUITING

The Royal Marsden NHS Foundation Trust, Sutton